Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag
Pfizer announced Friday morning that the FDA approved its gene therapy for the rare genetic bleeding disorder hemophilia B.
The one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
